Search

Your search keyword '"antiangiogenesis"' showing total 1,530 results

Search Constraints

Start Over You searched for: Descriptor "antiangiogenesis" Remove constraint Descriptor: "antiangiogenesis"
1,530 results on '"antiangiogenesis"'

Search Results

301. Antiangiogenic Treatment of Meningiomas.

302. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.

303. Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

304. Corneal neovascularization and contemporary antiangiogenic therapeutics.

305. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.

306. An arabinogalactan from flowers of Panax notoginseng inhibits angiogenesis by BMP2/Smad/Id1 signaling.

307. Development and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.

308. Deltonin inhibits angiogenesis by regulating VEGFR2 and subsequent signaling pathways in endothelial cells.

309. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.

310. Immune Effects of Bevacizumab: Killing Two Birds with One Stone.

311. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges

312. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

313. MicroRNAs as crucial mediators in the pharmacological activities of triptolide (Review)

314. Convection-Enhanced Delivery of Antiangiogenic Drugs and Liposomal Cytotoxic Drugs to Heterogeneous Brain Tumor for Combination Therapy

315. Fibroblast-Mimicking nanodecoys for Multi-Target antiangiogenesis in the inflammation treatment.

316. Ricinus communis Butanol Fraction Inhibits MCF-7 Breast Cancer Cell Migration, Adhesion, and Invasiveness

317. Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review

318. Antiangiogenic properties of lichen secondary metabolites

319. A low-molecular-weight chitosan fluorometric-based assay for evaluating antiangiogenic drugs.

320. Novel hKDR mouse model depicts the antiangiogenesis and apoptosis-promoting effects of neutralizing antibodies targeting vascular endothelial growth factor receptor 2.

321. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.

322. Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau

323. Novel metal complexes of naphthalimide–cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: Synthesis and biological evaluation.

324. Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents.

325. Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.

326. New Targets and New Drug Development in Colorectal Cancer.

327. Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter.

328. Insights into the role of components of the tumor microenvironment in oral carcinoma call for new therapeutic approaches.

329. Metallo-drugs as nitric oxide (NO•) and/or nitroxyl(HNO) donors : development of new agents and investigation of anticancer, antihypertensive and antituberculosis activities

330. Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?

331. Preparation, antiangiogenic and antitumoral activities of the chemically sulfated glucan from Phellinus ribis.

332. Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.

333. Management of Colon Cancer and Liver Metastases: Is There a Role for Molecularly Targeted Agents?

334. New role of lupeol in reticence of angiogenesis, the cellular parameter of neoplastic progression in tumorigenesis models through altered gene expression.

335. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.

336. Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II.

337. Multicompartimental Nanoparticles for Co-Encapsulation and Multimodal Drug Delivery to Tumor Cells and Neovasculature.

338. Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.

339. Antiangiogenic Effect of Ficus deltoidea Jack Standardised Leaf Extracts.

340. Syringic acid exerts antiangiogenic activity by downregulation of VEGF in zebrafish embryos.

341. Antiangiogenic Effect of Docetaxel and Everolimus as Individual and Dual-Drug-Loaded Micellar Nanocarriers.

342. In vitro and in vivo mechanistic study of a novel proanthocyanidin, GC-(4→8)-GCG from cocoa tea (Camellia ptilophylla) in antiangiogenesis.

343. Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin

344. Using an Observer in a Sliding Mode for Modeling Antiangiogenic Therapy

345. Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients.

346. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme.

347. Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.

348. Antiangiogenic Activity of Quinine Alone and in Combination with vitamin C in both ex vivo and in vivo Assays.

349. Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review

350. Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis.

Catalog

Books, media, physical & digital resources